These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 11738123)

  • 21. Recruitment strategies and challenges in a large intervention trial: Systolic Blood Pressure Intervention Trial.
    Ramsey TM; Snyder JK; Lovato LC; Roumie CL; Glasser SP; Cosgrove NM; Olney CM; Tang RH; Johnson KC; Still CH; Gren LH; Childs JC; Crago OL; Summerson JH; Walsh SM; Perdue LH; Bankowski DM; Goff DC;
    Clin Trials; 2016 Jun; 13(3):319-30. PubMed ID: 26911833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of hospitalized gastrointestinal bleeding in persons randomized to diuretic, ACE-inhibitor, or calcium-channel blocker in ALLHAT.
    Phillips W; Piller LB; Williamson JD; Whittle J; Jafri SZ; Ford CE; Einhorn PT; Oparil S; Furberg CD; Grimm RH; Alderman MH; Davis BR; Probstfield JL;
    J Clin Hypertens (Greenwich); 2013 Nov; 15(11):825-32. PubMed ID: 24283598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial.
    Alderman MH; Piller LB; Ford CE; Probstfield JL; Oparil S; Cushman WC; Einhorn PT; Franklin SS; Papademetriou V; Ong ST; Eckfeldt JH; Furberg CD; Calhoun DA; Davis BR;
    Hypertension; 2012 May; 59(5):926-33. PubMed ID: 22431578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13 ) on the effectiveness of statins: the GenHAT study.
    Maitland-van der Zee AH; Peters BJ; Lynch AI; Boerwinkle E; Arnett DK; Cheng S; Davis BR; Leiendecker-Foster C; Ford CE; Eckfeldt JH
    Pharmacogenet Genomics; 2009 May; 19(5):338-44. PubMed ID: 19415820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Cushman WC; Ford CE; Einhorn PT; Wright JT; Preston RA; Davis BR; Basile JN; Whelton PK; Weiss RJ; Bastien A; Courtney DL; Hamilton BP; Kirchner K; Louis GT; Retta TM; Vidt DG;
    J Clin Hypertens (Greenwich); 2008 Oct; 10(10):751-60. PubMed ID: 19090876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study.
    Maitland-van der Zee AH; Lynch A; Boerwinkle E; Arnett DK; Davis BR; Leiendecker-Foster C; Ford CE; Eckfeldt JH
    Pharmacogenet Genomics; 2008 Aug; 18(8):651-6. PubMed ID: 18622257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How to get older people included in clinical studies.
    Witham MD; McMurdo ME
    Drugs Aging; 2007; 24(3):187-96. PubMed ID: 17362048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study.
    Maitland-van der Zee AH; Boerwinkle E; Arnett DK; Davis BR; Leiendecker-Foster C; Miller MB; Klungel OH; Ford CE; Eckfeldt JH
    Am Heart J; 2007 Jan; 153(1):54-8. PubMed ID: 17174637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics and lipid distribution of a large, high-risk, hypertensive population: the lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Papademetriou V; Piller LB; Ford CE; Gordon D; Hartney TJ; Geraci TS; Reisin E; Sumner BM; Wong ND; Nwachuku C; Narayan P; Haywood J; Habib G;
    J Clin Hypertens (Greenwich); 2003; 5(6):377-84. PubMed ID: 14688492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recruitment, retention, and compliance results from a probability study of children's environmental health in economically disadvantaged neighborhoods.
    Sexton K; Adgate JL; Church TR; Greaves IA; Ramachandran G; Fredrickson AL; Geisser MS; Ryan AD
    Environ Health Perspect; 2003 May; 111(5):731-6. PubMed ID: 12727602
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What ALLHAT tells us about treating high-risk patients with hypertension and hyperlipidemia.
    Geraci TS; Geraci SA
    J Cardiovasc Nurs; 2003; 18(5):389-95. PubMed ID: 14680343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Experimental approaches to determining the choice of first-step therapy for patients with hypertension. The ALLHAT Research Group Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.
    Whelton PK; Williamson JD; Louis GT; Davis BR; Cutler JA
    Clin Exp Hypertens; 1996; 18(3-4):569-79. PubMed ID: 8743044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Pressel S; Davis BR; Louis GT; Whelton P; Adrogue H; Egan D; Farber M; Payne G; Probstfield J; Ward H;
    Control Clin Trials; 2001 Dec; 22(6):674-86. PubMed ID: 11738123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.
    Davis BR; Cutler JA; Gordon DJ; Furberg CD; Wright JT; Cushman WC; Grimm RH; LaRosa J; Whelton PK; Perry HM; Alderman MH; Ford CE; Oparil S; Francis C; Proschan M; Pressel S; Black HR; Hawkins CM
    Am J Hypertens; 1996 Apr; 9(4 Pt 1):342-60. PubMed ID: 8722437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Pressel SL; Davis BR; Wright JT; Geraci TS; Kingry C; Ford CE; Piller LB; Bettencourt J; Kimmel B; Lusk C; Parks H; Simpson LM; Nwachuku C; Furberg CD;
    Control Clin Trials; 2001 Feb; 22(1):29-41. PubMed ID: 11165421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): clinical center recruitment experience.
    Wright JT; Cushman WC; Davis BR; Barzilay J; Colon P; Egan D; Lucente T; Nwachuku C; Pressel S; Leenen FH; Frolkis J; Letterer R; Walsh S; Tobin JN; Deger GE;
    Control Clin Trials; 2001 Dec; 22(6):659-73. PubMed ID: 11738122
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.